Slides
Page 1
Q2 2026 Earnings Presentation FMC CORPORATION 1 Q2 2026 Earnings Presentation July 30, 2026
Page 2
Q2 2026 Earnings Presentation FMC CORPORATION 2 Safe Harbor Statement 2FMC CORPORATION Non-GAAP Financial Terms These slides contain certain “non-GAAP financial terms”. Such non-GAAP financial terms include adjusted EBITDA, adjusted EBITDA margin ex. India, adjusted EPS, adjusted tax rate, free cash flow ("FCF"), organic revenue growth, revenue excluding India and return on invested capital. Definitions of these terms, as well as a reconciliation to the most directly comparable financial measure calculated and presented in accordance with GAAP, are provided on our website investors.fmc.com. Although we provide forecasts for these non-GAAP financial measures, we are not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP. Certain elements of the composition of the GAAP amounts are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to restructuring, acquisition charges, our India held for sale business and discontinued operations and related cash activity. As a result, no GAAP outlook is provided. All references herein to “EBITDA” are shorthand references to Adjusted EBITDA and do not signify EBITDA before adjustments. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements made in this presentation are forward- looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook for our company based on currently available information. In some cases, you can identify these forward-looking statements by such words or phrases as “outlook”, "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward- looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward- looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.
Page 3
Q2 2026 Earnings Presentation FMC CORPORATION 3 FMC Advancing on 2026 Operational Priorities Generate ~$1B of Proceeds for Debt Paydown Improve Competitiveness of Core Portfolio Grow Sales of New Active Ingredients Sale of India commercial business Active ingredient licensing including upfront payment Lower manufacturing costs of non-diamide core products Adjust Asia cost structure to account for smaller size following India commercial sale Sales expected to reach $300M to $400M in 2026 Commercial licensing agreements accelerate growth Continue strategy to increase direct-to-grower sales in Brazil Implement Post-Patent Rynaxypyr® Strategy Offer advanced mixtures and formulations: Differentiate from solo offerings and address resistance challenges Lower price to grow volume by capturing market share from other, older insecticides Continue to lower Rynaxypyr® manufacturing costs Property leaseback and other asset sales Successful $1.2 billion secured bond offering completed in May Strategic review complete; Company continues to focus on operational priorities Equity investment from Tessenderlo Group
Page 4
Q2 2026 Earnings Presentation FMC CORPORATION 4 Q2 2026 Results Q2 2026 HIGHLIGHTS ❖ Volume decline driven by diamide partners and core legacy products ❖ Higher sales in growth portfolio driven by new actives and Cyazypyr® ❖ Branded Rynaxypyr® sales in-line with prior year excluding India ❖ Received registration for Isoflex® in the European Union ❖ Pricing pressure more pronounced in LATAM ❖ Adjusted EPS1 decline due to lower EBITDA1 and higher interest expense Q2 2026 Q2 20252 2026 VS. 2025 GAAP Revenue Revenue ex. India1 $867 $841 $1,051 (17)% (20)% GAAP Net Income (Loss) $(187) $67 $(253) Adjusted EBITDA1 $153 $207 (26)% % Revenue (ex. ’26 India) 18.1% 19.7% (160) bps GAAP EPS $(1.49) $0.53 $(2.02) Adjusted EPS1 $0.26 $0.69 (62)% 4FMC CORPORATION Note: Amounts in millions of USD except for EPS; variances may not sum due to rounding 1. Denotes non-GAAP financial term. Refer to “Non-GAAP Financial Terms” at the beginning of this presentation. 2. Q2 2025 Revenue included India results
Page 5
Q2 2026 Earnings Presentation FMC CORPORATION 5 Q2 2026 Regional Revenue Drivers VOLUME PRICE FX India (Q2 2025) Total: -20% -10% -7% 2% -5% Organic1: -22% • Lower partner sales primary driver of sales decline • Strong branded volume growth in Brazil including fluindapyr-based fungicide Onsuva® • Expected registration losses and high heat across region negatively impacted volumes • Growth of new active ingredients driven by Isoflex® • Competitive market and tight grower margins led to lower volumes • Solid growth of branded Rynaxypyr® driven by new products • Sale of India commercial business was the primary driver of lower sales versus prior year • Solid growth in Australia & New Zealand Latin America $278 million (-10% YoY, -16% ex-FX) Asia2 $101 million (-37% YoY, -38% ex-FX) North America $249 million (-22% YoY, -23% ex-FX) EMEA $214 million (-18% YoY, -19% ex-FX) Q2 2026 REVENUE DRIVERS (Excluding India)1 ($6) ($46) $1,051 ($52) $999 ($72) ($32) $841 Q2 '25 '25 India '25 Ex. India NA LATAM Asia EMEA Q2 '26 1. Denotes non-GAAP financial term. Refer to “Non-GAAP Financial Terms” at the beginning of this presentation. 2. Excludes 2026 India, includes 2025 India; on a like-for-like basis Asia sales were down 6% year-over-year REGIONAL REVENUE BRIDGE (Excluding India)1 Note: Amounts in millions of USD; “Asia” column excludes India; totals may not sum due to rounding 2 Lower branded pricing in all regions with LATAM reporting highest pricing pressure
Page 6
Q2 2026 Earnings Presentation FMC CORPORATION 6 Q2 2026 Adjusted EBITDA1 Drivers Note: Amounts in millions of USD Adjusted EBITDA1 BRIDGE KEY DRIVERS AT A GLANCE Volume, Mix, Launches Cost • Strong growth of new active ingredients • Lower volume driven almost entirely by lower diamide partner sales and core legacy products • Cost favorability mainly within gross margin including favorable raw materials and supply chain improvements Price FX • Lower price due to pressure on core legacy products and branded Rynaxypyr® pricing strategy • More pronounced reductions in LATAM • Tailwind mainly due to BRL $0 ($47) $6 $207 $207 ($75) $62 $153 Q2 '25 India Q2 '25 ex. India Volume, Mix, … Price Cost FX Q2 '26 1. Denotes non-GAAP financial term. Refer to “Non-GAAP Financial Terms” at the beginning of this presentation. 6FMC CORPORATION Q2 ‘25 India Q2 ‘25 ex. India Volume, Mix, Launches Price Cost FX Q2 ‘26
Page 7
Q2 2026 Earnings Presentation FMC CORPORATION 7 FY 2026 Financial Outlook 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation 2. Outlook for EPS assumes weighted average diluted shares outstanding (WADSO) of 125.9 million 3. Includes H1 ’25 India contribution; represents 2% headwind to full year revenue Note: Year-over-year growth noted at mid-point of guidance range $620 million – $680 million • Lower price • Favorable costs • FX headwind (23)% YoY3 $1.19 – $1.49 (55)% YoY3 • Excluding India, volume in line with prior year • 50%+ growth in new active ingredients • Increase in direct sales in Brazil • Higher sales in EMEA and LATAM • Price down mid to high-single digits • FX low-single digit tailwind $3.50 billion – $3.70 billion (7)% YoY3 • Lower EBITDA1 • Higher interest expense REVENUE excl. India1ADJ. EBITDA1ADJ. EPS1,2 REVENUE (excl. India)1 DRIVERS ADJ. EPS1,2 DRIVERS ADJ. EBITDA1 DRIVERS FY 2026 Guidance
Page 8
Q2 2026 Earnings Presentation FMC CORPORATION 8 Q3 2026 Financial Outlook 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation 2. Outlook for EPS assumes weighted average diluted shares outstanding (WADSO) of 125.9 million Note: Year-over-year growth noted at mid-point of guidance range $120 million – $140 million • Lower price • Lower volume • FX headwind (45)% YoY3 $0.05 – $0.13 (90)% YoY • Mid to high-single digit price decline • Lower volumes driven by North America distributors shifting orders to Q4 to align purchases closer to timing of application $840 million – $900 million (9)% YoY • Lower EBITDA1 • Higher interest expense REVENUE excl. India1ADJ. EBITDA1ADJ. EPS1,2 REVENUE (excl. India)1 DRIVERS ADJ. EPS1,2 DRIVERS ADJ. EBITDA1 DRIVERS Q3 2026 Guidance • Growth of new active ingredients • FX neutral
Page 9
Q2 2026 Earnings Presentation FMC CORPORATION 9 Q4 2026 Financial Outlook 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation 2. Outlook for EPS assumes weighted average diluted shares outstanding (WADSO) of 125.9 million Note: Year-over-year growth noted at mid-point of guidance range $275 million – $315 million • Higher volume • Favorable costs • Lower price • FX headwind5% YoY $1.09 – $1.33 1% YoY • Higher volume due to: o Increase in direct sales to growers in Brazil o New active ingredients including fluindapyr-based fungicide Adastrio® in North America and Isoflex® herbicide in Australia and Great Britain o North America distributor order shift from Q3 to Q4 $1.06 billion – $1.20 billion 4% YoY • Higher EBITDA1 • Higher interest expense REVENUE excl. India1ADJ. EBITDA1ADJ. EPS1,2 REVENUE (excl. India)1 DRIVERS ADJ. EPS1,2 DRIVERS ADJ. EBITDA1 DRIVERS Q4 2026 Guidance • Mid to high-single digit price decline • FX neutral
Page 10
Q2 2026 Earnings Presentation FMC CORPORATION 10 '26 EBITDA Midpoint Interest & Tax CapEx & OIA Restruct. & Legacy Licensing Working Capital & Other '26 FCF Midpoint Q2 Cash Results and 2026 Cash Flow Guidance 1. Denotes non-GAAP financial term. Refer to “Non-GAAP Financial Terms” at the beginning of this presentation. In Millions Q2 ‘26 Q2 ‘25 Q2 ’26 vs. Q2 ’25 FY 2026 Guidance Adjusted EBITDA1 $153 $207 $(54) $620 - $680 Cash from Operations (GAAP) $363 $66 $297 $200 - $320 Capital Additions & Other Investing Activities (OIA) $6 $(10) $16 $(50) - $(70) Discontinued Operations $(19) $(16) $(2) $(70) - $(80) Divestiture Transaction Costs $7 $0 $7 ~$25 Free Cash Flow (FCF)1 $357 $40 $318 $75 - $225 Note: Restructuring cash costs of $26 million in Q2 2026, $15 million in Q2 2025 and an estimate of ~$170 million for the full year are included in GAAP Cash from Operations. Bridge between Cash from Operations and Free Cash Flow, as well as quarterly variances, may not sum due to rounding. $650M $150M 2026 Outlook • Free Cash Flow1 guidance updated $75M to $225M • Working capital release includes expected contributions from India • Now includes $200 million upfront rimisoxafen licensing payment • ~$170M of restructuring spend Q2 Cash Results • $200M from rimisoxafen upfront licensing payment included • Working capital release including India contribution 1 1
Page 11
Q2 2026 Earnings Presentation FMC CORPORATION 11 APPENDIX
Page 12
Q2 2026 Earnings Presentation FMC CORPORATION 12 Appendix Revenue: ~$90 million EBITDA: $0 million 16 – 18 percent $275 million – $285 million $160 million – $170 million ~125.9 million $75 million – $225 million $50 – $70 million 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation. Modeling Assumptions for 2026 INTEREST EXPENSE ADJUSTED TAX RATE1 2026 EXPECTED INDIA LOSS OF CONTRIBUTION FULL-YEAR WEIGHTED AVG. DILUTED SHARES OUTSTANDING (WADSO) DEPRECIATION & AMORTIZATION FREE CASH FLOW1 CAPITAL ADDITIONS AND OTHER INVESTING ACTIVITIES 12Q2 2026 Earnings Presentation FMC CORPORATION $1 million – $3 million NON-CONTROLLING INTEREST
Page 13
Q2 2026 Earnings Presentation FMC CORPORATION 13 Adj. EBITDA1 INT. EXPENSE D&A OTHER Q2 ‘26Q2 ‘25 Q2 2026 Adjusted EPS1 Variance Appendix $0.69 $0.26 $(0.37) $(0.07) $0.02 $(0.01) 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation
Page 14
Q2 2026 Earnings Presentation FMC CORPORATION 14 Additional Disclaimers Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. No offer for sale, sale, or use of any such products is permitted prior to the issuance of the required U.S. EPA andstate registrations, or other applicable regulatory authority restrictions. FMC, Adastrio, Cyazypyr, Isoflex, Onsuva, Rynaxypyr and the FMC logo are trademarks of FMC Corporation or an affiliate.
Page 15
Q2 2026 Earnings Presentation FMC CORPORATION 15 Copyright © 2026, FMC Corporation. All Rights Reserved.